Sandoz Hit With Patent Suit Over Bausch's IBS Drug Xifaxan
Bausch Health and its gastrointestinal medicine subsidiary said Tuesday that they sued Novartis unit Sandoz Inc. for allegedly infringing 14 patents for the irritable bowel syndrome drug Xifaxan....To view the full article, register now.
Already a subscriber? Click here to view full article